Gabriella Ferrandina

Molecular alterations of the <i>AKT</i>2 oncogene in ovarian and breast carcinomas

Alfonso Bellacosa, Daniela de Feo, Andrew K. Godwin et al. · International Journal of Cancer · 1995 · 836 citations

Medicine, Genetics, Oncology +14

A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study

Anna Fagotti, Gabriella Ferrandina, Francesco Fanfani et al. · Annals of Surgical Oncology · 2006 · 402 citations

Medicine, Gynecology, Surgery +17

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome

Anna Fagotti, Gabriella Ferrandina, Giuseppe Vizzielli et al. · European Journal of Cancer · 2016 · 397 citations

Medicine, Oncology, Surgery +11

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 392 citations

Medicine, Gynecology, Oncology +12

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Simona Mozzetti, Cristiano Ferlini, Paola Concolino et al. · PubMed · 2005 · 327 citations

Medicine, Oncology, Pharmacology +16